AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 14, 2023

Indian healthcare looks at pharmacogenomics, the study of influence of genetic factors on drug response, in patient care as comprehensive genetic tests gain ground.

Genetics 147

Genetics Drugs Clinical Trials Clinical Trials 147

STAT News

DECEMBER 10, 2022

NEW ORLEANS — An emerging class of genetically targeted drugs is inducing remissions in about one-third of patients with advanced leukemia, according to updates Saturday from separate clinical trials. Continue to STAT+ to read the full story…

Genetics 141

Genetics Drugs Clinical Trials Clinical Trials 141

Pharmaceutical Technology

NOVEMBER 8, 2022

Fulgent Genetics has acquired clinical-stage therapeutics development firm Fulgent Pharma for a total deal price of nearly $100m. According to the deal, the purchase price, contingent on adjustments, has to be paid by Fulgent Genetics as a combination of cash on hand and its shares of common stock.

Genetics 130

Genetics Development Genome Genomics 130

Bio Pharma Dive

MARCH 26, 2024

The biotech is trying to develop a Spinraza-like drug for the condition, a form of genetic epilepsy. Fresh data appear supportive of a high dose’s effectiveness.

Drugs 164

Drugs Genetics Development 164

pharmaphorum

JANUARY 24, 2023

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

Genetics 95

Genetics Drugs Genome Project Biobanking 95

Medical Xpress

MAY 3, 2023

New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS. The University of Bristol-led study, published in Arthritis & Rheumatology, analyzed genetic data on nearly 34,000 people.

Genetics 96

Genetics Drugs Research 96

Medical Xpress

FEBRUARY 3, 2023

Patients can experience 30% fewer serious adverse reactions if their drugs are tailored to their genes, reports a study published in The Lancet. A European collaboration involving researchers from Karolinska Institutet suggests that a genetic analysis prior to drug therapy could significantly reduce suffering and health care costs.

Genetic Analysis 97

Genetic Analysis Genetics Drugs Gene 97

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Genetically modified animal models. Regeneron Pharmaceuticals is one of the leading patent filers in the generation of genetically modified animal models.

Genetics 130

Genetics DNA Antibody Genome 130

Bio Pharma Dive

FEBRUARY 12, 2021

The biotech set an average annual price of $450,000 for the first-of-its-kind drug, which treats a condition that affects about 1,300 people in the U.S.

FDA Approval 294

FDA Approval Genetics Drugs 294

Eye on FDA

MARCH 7, 2024

Back in December 2023, FDA announced intention in the Federal Register and in a press release to form a new FDA Advisory Committee to be called the Genetic Metabolic Diseases Advisory Committee (GeMDAC). The vote of any committee is advisory in nature, and not binding on the agency’s final decision.

Genetics 78

Genetics Drugs Medicine Development 78

Bio Pharma Dive

AUGUST 24, 2022

The New York biotech will invest in and develop up to three drugs with Gensaic, an emerging startup aiming to use the viruses that infect bacteria to deliver genetic medicines.

Gene Therapy 279

Gene Therapy Bacteria Gene Drugs 279

Bio Pharma Dive

NOVEMBER 7, 2022

Buoyed by strong mid-stage study results, the biotech will soon start a cardiovascular outcomes trial of a drug designed to target a genetic risk factor called lipoprotein(a).

Drug Trials 282

Drug Trials Trials Genetics Drugs 282

XTalks

MARCH 28, 2024

Italy-based drugmaker Italfarmaco has won US Food and Drug Administration (FDA) approval for its oral medication Duvyzat (givinostat) for the treatment of Duchenne muscular dystrophy (DMD) in patients six years of age and older. The global incidence of DMD is approximately one in every 3,500 to 6,000 male births.

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here. CIGB is headquartered in Cuba.

Genetic Engineering 100

Genetic Engineering Engineer Genetics Clinical Trials 100

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here. CIGB is headquartered in Cuba.

Genetic Engineering 100

Genetic Engineering Engineer Genetics Clinical Trials 100

pharmaphorum

MARCH 26, 2021

There’s a new kid on the block among companies using artificial intelligence in drug discovery, after 1910 Genetics launched today with $26 million in financing. 1910 Genetics is named after the year in which sickle cell disease (SCD) was first discovered in the US by James Herrick. Dr Jen Nwankwo.

Genetics 102

Genetics Drugs Protein Scientist 102

Drug Discovery World

JULY 14, 2023

University of Queensland (UQ) researchers have used genetics to reveal that much of the risk of developing the common and sometimes fatal diverticular disease of intestine (DivD) is inherited. The study has identified new drug targets and opened up possibilities for novel treatment strategies.

Genetics 52

Genetics Drugs Gene Genome 52

Pharma Mirror

FEBRUARY 23, 2021

The post Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site appeared first on Pharma Mirror Magazine. SOMERSET, N.J. SOMERSET, N.J. Catalent is also announcing the launch of pDNA development and manufacturing services at its Rockville, Maryland facility.

Genetics 130

Genetics Manufacturing Gene Therapy DNA 130

Scienmag

FEBRUARY 10, 2022

Drugs to increase insulin signaling may be effective for treating autism say Lancaster University researchers, who have discovered how a genetic change impacts on insulin signaling and glucose metabolism in the brain.

Genetics 80

Genetics Insulin Drugs Research 80

BioSpace

MARCH 25, 2024

Stoke Therapeutics reported results for Dravet syndrome studies showing clinically meaningful effects, including reductions in convulsive seizure frequency, supporting the potential for disease modification.

Genetics 119

Genetics Drugs 119

pharmaphorum

JUNE 9, 2023

3rd Rare & Genetic Kidney Disease Drug Development Summit Mike.Hammerton Fri, 09/06/2023 - 07:13 Bookmark this

Genetics 52

Genetics Development Drugs 52

Drug Discovery World

MARCH 18, 2024

Landmark genetic research could allow doctors to accurately predict whether a patient is at risk of developing common diseases, decades before any symptoms would become evident. The post $8 million awarded to landmark genetic research project appeared first on Drug Discovery World (DDW).

Genetics 52

Genetics Research Genome Genomics 52

Pharmaceutical Technology

MAY 10, 2023

Synlogic has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for SYNB1934 to treat phenylketonuria (PKU), a rare inherited metabolic disease. The orally administered, non-systemically absorbed drug candidate SYNB1934 has been designed for reducing blood phenylalanine (Phe) levels in PKU patients.

Genetic Engineering 261

Genetic Engineering Drugs Engineer Genetics 261

Bio Pharma Dive

AUGUST 9, 2023

The Flagship-backed company claims its technology can create genetic drugs that work broadly to treat diseases caused by “stop” mutations.

RNA 130

RNA Drugs Genetics 130

Drug Discovery World

JANUARY 19, 2024

UK scientists have uncovered the interplay between cancer-driving genetic mutations and inherited genetic variants in a rare type of blood cancer. In the future, this knowledge could aid drug development and interventions that reduce the risk of disease.

Genetics 59

Genetics Gene DNA Development 59

Bio Pharma Dive

JANUARY 24, 2024

An 11-year-old boy born deaf can hear after receiving Lilly's genetic medicine. are taking aim at the same drug target. Others, including biotechs in China and Regeneron in the U.S.,

Gene Therapy 287

Gene Therapy Gene Genetics Medicine 287

STAT News

MARCH 11, 2023

The Food and Drug Administration on Friday approved the first treatment for Rett syndrome, a genetic disease mostly affecting girls that causes severe neurologic impairments, robbing them of the ability to communicate or control muscle movement. The new drug, called Daybue, is made by Acadia Pharmaceuticals.

Genetics 98

Genetics FDA Approval Genetic Disease Clinical Trials 98

pharmaphorum

MARCH 10, 2022

18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round financing that it will use to take its own genetic modifier-targeted medicines into clinical trials. Scenic has developed a series of small-molecule drugs targeting QPTCL that block the expression of CD47 on cancer cells.

Genetics 98

Genetics Gene Sequencing Gene Clinical Trials 98

Drug Discovery World

JUNE 8, 2023

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with Dr Pierre Eftehkari, Chief Sceitnific Officer of Inoviem Scientific.

Genetics 52

Genetics Medicine Drugs Development 52

Drug Discovery World

APRIL 9, 2024

The scientists genetically modified dendritic cells to produce CXCL9 and CXCL10 and then injected these directly into the tumours in mouse models of NSCLC. Diana Spencer, Senior Digital Content Editor, DDW The post Genetically engineered dendritic cells enhance lung cancer therapy appeared first on Drug Discovery World (DDW).

Genetic Engineering 52

Genetic Engineering Engineer Genetics Immune Response 52

Drug Discovery World

OCTOBER 5, 2023

A research team at the Francis Crick Institute and Great Ormond Street Hospital (GOSH)/UCL Great Ormond Street Institute of Child Health have identified potential treatments for children with rare genetic conditions. Both treatments were able to improve the calcium problems, but the genetic therapy was the most effective.

Genetics 59

Genetics Research Gene Doctors 59

Bio Pharma Dive

JUNE 3, 2021

Study results disclosed ahead of ASCO could make Lynparza a standard "adjuvant" treatment for people with an inherited form of breast cancer — as long as they know they have it.

Genetics 355

Genetics Drugs 355

Outsourcing Pharma

JANUARY 23, 2024

Sano Genetics says it is developing software that will enable âthe precision medicine revolutionâ and has raised $11.4 million in new funding.

Genetics 82

Genetics Medicine Development Drug Delivery 82

STAT News

DECEMBER 13, 2022

A new study suggests that the root of the problem is buried in our genetic code. Medicines that reshape or tamp down immune responses may be life-changing for patients with cancer and autoimmune disorders, but in some cases they can awaken a dormant virus and unleash a deadly brain disease.

Genetics 105

Genetics Immune Response Gene Drugs 105

pharmaphorum

MARCH 21, 2022

Neuroscience is arguably the next great frontier in medicine and 2022 dawned with a wave of exhilarating progress for the neurodegenerative drug development community. The post Welcome to 1st Rare & Genetic Neurodegenerative Drug Development Summit appeared first on.

Genetics 52

Genetics Development Drugs Gene Therapy 52

Bio Pharma Dive

DECEMBER 12, 2021

But despite continued setbacks, drug developers are hopeful that genetic technologies and a better understanding of biology will bring new options in the not-too-distant future The fatal nerve disease has few treatments.

Genetics 256

Genetics Drugs Research Development 256

Drug Discovery World

JULY 26, 2023

CPVT is a rare genetic heart disease causing arrhythmia. In addition to CPVT, this unique mechanism of ARM210 has potential use in other RyR-mediated cardiac and skeletal muscle diseases, such as the genetic muscle disorder Ryanodine Receptor 1-Related Myopathy (RYR1-RM).

Genetics 52

Genetics Trials Drugs Clinical Trials 52